What Are the Best Medications for Treating Plaque Psoriasis?
For individuals diagnosed with plaque psoriasis—the most common form of psoriasis—treatment selection depends on disease severity, extent of skin involvement, impact on quality of life, and presence o
For individuals diagnosed with plaque psoriasis—the most common form of psoriasis—treatment selection depends on disease severity, extent of skin involvement, impact on quality of life, and presence of comorbidities such as psoriatic arthritis or cardiovascular risk factors.
Mild to moderate plaque psoriasis is typically managed with topical therapies, including corticosteroids, vitamin D analogs (e.g., calcipotriene), retinoids (e.g., tazarotene), and calcineurin inhibitors. These agents help reduce epidermal hyperproliferation, inflammation, and scaling.
In cases of moderate to severe disease—defined as involvement of more than 10% body surface area, significant functional impairment, or failure to respond adequately to topical treatment—systemic therapies are indicated. Conventional systemic agents include methotrexate, cyclosporine, and acitretin. Each carries distinct efficacy profiles and safety considerations: methotrexate requires monitoring of liver enzymes and blood counts; cyclosporine necessitates regular assessment of renal function and blood pressure; and acitretin demands strict pregnancy prevention due to its teratogenicity.
Biologic therapies represent a major advancement in psoriasis management. TNF-alpha inhibitors (e.g., adalimumab, infliximab, ustekinumab), IL-12/23 inhibitors (e.g., ustekinumab), IL-23 inhibitors (e.g., guselkumab, risankizumab), and IL-17 inhibitors (e.g., secukinumab, ixekizumab, brodalumab) offer high rates of skin clearance and durable responses. Selection among biologics considers individual patient factors—including comorbid inflammatory conditions, infection history, prior treatment response, and pharmacokinetic preferences (e.g., subcutaneous vs. intravenous administration).
JAK inhibitors, such as deucravacitinib—a selective TYK2 inhibitor—have recently expanded the oral therapeutic landscape, offering an effective non-biologic systemic option with a favorable safety profile relative to older JAK inhibitors.
Treatment decisions should always be made collaboratively between patients and dermatologists, incorporating shared decision-making, long-term safety monitoring, and periodic reassessment of therapeutic goals and disease activity.